Lai Ching-te’s stopovers in New York and California are scheduled to take place on his way to and from Paraguay for the inauguration of its new president.
Oliver Dorigo, MD, PhD, explains how MVP-S leverages the DPX platform to produce persistent anti-survivin immune infiltration, highlights the antitumor activity and safety observed with the combination when given to patients with recurrent ovarian cancer, and describes additional research efforts underway.